Blog

Switching on electrocatalytic activity in solid oxide cells

Solid oxide cells (SOCs) can operate with high efficiency in two ways—as fuel cells, oxidizing a fuel to produce electricity, and as electrolysis cells, electrolysing water to produce hydrogen and oxygen gases. Ideally, SOCs should perform well, be durable and be inexpensive, but there are often competitive tensions, meaning that, for example, performance is achieved at the expense of durability. SOCs consist of porous...

More Comments are closed
Cooperative electrocatalytic alcohol oxidation with electron-proton-transfer mediators

The electrochemical oxidation of alcohols is a major focus of energy and chemical conversion efforts, with potential applications ranging from fuel cells to biomass utilization and fine-chemical synthesis. Small-molecule electrocatalysts for processes of this type are promising targets for further development, as demonstrated by recent advances in nickel catalysts for electrochemical production and oxidation of hydrogen. Complexes with tethered amines that resemble the active...

More Comments are closed
Cooperative electrocatalytic alcohol oxidation with electron-proton-transfer mediators

The electrochemical oxidation of alcohols is a major focus of energy and chemical conversion efforts, with potential applications ranging from fuel cells to biomass utilization and fine-chemical synthesis. Small-molecule electrocatalysts for processes of this type are promising targets for further development, as demonstrated by recent advances in nickel catalysts for electrochemical production and oxidation of hydrogen. Complexes with tethered amines that resemble the active...

More Comments are closed
.NET Core 1.0 released, now officially supported by Red Hat

Version 1.0 of .NET Core, the open source, cross-platform .NET runtime platform that was first announced in 2014, has been released today. .NET Core is arriving alongside ASP.NET Core 1.0, the open source, cross-platform version of Microsoft's Web development stack.

Microsoft picked an unusual venue to announce the release: the Red Hat Summit. One of the...

More Comments are closed
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117, a broad and potent neutralizing antibody (bNAb) against the CD4 binding site of HIV-1 Env1, in the setting of analytical treatment interruption (ATI) in 13 HIV-1-infected individuals. Participants with 3BNC117-sensitive virus outgrowth cultures were enrolled....

More Comments are closed